Arvee Laboratories (India) Limited (ARVEE) - Total Liabilities
Based on the latest financial reports, Arvee Laboratories (India) Limited (ARVEE) has total liabilities worth Rs91.40 Million INR (≈ $988.48K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Arvee Laboratories (India) Limited operating cash flow efficiency to assess how effectively this company generates cash.
Arvee Laboratories (India) Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Arvee Laboratories (India) Limited's total liabilities have evolved over time, based on quarterly financial data. Check Arvee Laboratories (India) Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Arvee Laboratories (India) Limited Competitors by Total Liabilities
The table below lists competitors of Arvee Laboratories (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Energoaparatura S.A.
WAR:ENP
|
Poland | zł15.31 Million |
|
Hifab Group AB Series B
ST:HIFA-B
|
Sweden | Skr60.58 Million |
|
Euroconsultants SA
AT:EUROC
|
Greece | €6.35 Million |
|
Khadim India Limited
NSE:KHADIM
|
India | Rs4.10 Billion |
|
Clean Seas Seafood Ltd
AU:CSS
|
Australia | AU$20.12 Million |
|
OCB Bhd
KLSE:5533
|
Malaysia | RM98.56 Million |
|
Devonian Health Group Inc
V:GSD
|
Canada | CA$5.97 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Arvee Laboratories (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARVEE stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arvee Laboratories (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arvee Laboratories (India) Limited (2013–2025)
The table below shows the annual total liabilities of Arvee Laboratories (India) Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs68.97 Million ≈ $745.87K |
-24.08% |
| 2024-03-31 | Rs90.85 Million ≈ $982.46K |
-14.48% |
| 2023-03-31 | Rs106.23 Million ≈ $1.15 Million |
-27.94% |
| 2022-03-31 | Rs147.43 Million ≈ $1.59 Million |
-24.81% |
| 2021-03-31 | Rs196.08 Million ≈ $2.12 Million |
+31.28% |
| 2020-03-31 | Rs149.36 Million ≈ $1.62 Million |
-27.80% |
| 2019-03-31 | Rs206.88 Million ≈ $2.24 Million |
-30.85% |
| 2018-03-31 | Rs299.18 Million ≈ $3.24 Million |
-4.96% |
| 2017-03-31 | Rs314.81 Million ≈ $3.40 Million |
-3.34% |
| 2016-03-31 | Rs325.69 Million ≈ $3.52 Million |
+32.32% |
| 2015-03-31 | Rs246.14 Million ≈ $2.66 Million |
+71.40% |
| 2014-03-31 | Rs143.60 Million ≈ $1.55 Million |
+62.92% |
| 2013-03-31 | Rs88.14 Million ≈ $953.24K |
-- |
About Arvee Laboratories (India) Limited
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroi… Read more